GLP-2(3-33) (C007B-357625)

GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor ( EC 50 =5.8 nM).In VitroGLP-2 is secreted as a 33-amino acid peptide, but is rapidly degraded at an N-terminus site to GLP-2(3-33) in circulation, in large part, by dipeptidylpeptidase IV (DPPIV). GLP-2 (3-33) acts as a partial agonist with potential competitive antagonistic properties on the GLP-2 receptor. In the GLP-2 receptor-binding assay, the binding IC 50 for GLP-2 1–33 was 3.1 nM, and it was 41 nM for GLP-2 3-33. Thus, GLP-2 3–33 had 7.5% binding affinity compared to GLP-2 1-33. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoGLP-2(3-33) (60 ng; once a day i.p. for 4 weeks) increases dyslipidemia and hepatic lipid accumulation in HFD-fed mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6J (B6) mice (HFD)Dosage: 60 ng Administration: Once a day i.p. for 4 weeks Result: Significantly affected plasma lipids; Showed increase of triglycerides and cholesterol and reduction of HDL; Significantly increased plasma ALT and AST and intrahepatic lipid concentration.Form:Solid. Specification: 0.99 Molecular Formula: C156H242N40O53S Molecular Weight: 3557.89